Literature DB >> 26962160

Chemotherapy for Bone Sarcoma in Adults.

Michael J Wagner1, J Andrew Livingston1, Shreyaskumar R Patel1, Robert S Benjamin2.   

Abstract

The largest studies of chemotherapy for bone sarcomas are in the pediatric population. Although increasing age is often found to be an adverse prognostic factor in these clinical trials, few studies are aimed at assessing regimens specifically in the adult population. Osteosarcoma and Ewing sarcoma have peak incidences in the pediatric and young adult population but also occur in adults. Chondrosarcoma and giant cell tumor of bone are generally found in adults. In this review, we describe the current status of our knowledge about treating adults with cancers of bone origin. We also describe our experience treating patients in the adult Sarcoma Medical Oncology group at The University of Texas MD Anderson Cancer Center.
Copyright © 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26962160     DOI: 10.1200/JOP.2015.009944

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  16 in total

Review 1.  Primary Osteosarcoma in the Elderly Revisited: Current Concepts in Diagnosis and Treatment.

Authors:  Rajendra Kumar; Meena Kumar; Kavin Malhotra; Shreyaskumar Patel
Journal:  Curr Oncol Rep       Date:  2018-02-28       Impact factor: 5.075

Review 2.  Advances in the management of primary bone sarcomas of the skull base.

Authors:  Idara Edem; Franco DeMonte; Shaan M Raza
Journal:  J Neurooncol       Date:  2020-04-18       Impact factor: 4.130

Review 3.  Surgical Treatment of Bone Sarcoma.

Authors:  Felix Bläsius; Heide Delbrück; Frank Hildebrand; Ulf Krister Hofmann
Journal:  Cancers (Basel)       Date:  2022-05-29       Impact factor: 6.575

4.  Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis.

Authors:  Lee D Cranmer; Bonny Chau; Jose G Mantilla; Elizabeth T Loggers; Seth M Pollack; Teresa S Kim; Edward Y Kim; Gabrielle M Kane; Matthew J Thompson; Jared L Harwood; Michael J Wagner
Journal:  Clin Orthop Relat Res       Date:  2022-04-01       Impact factor: 4.755

Review 5.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

Review 6.  Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives.

Authors:  Daniele Mercatelli; Massimo Bortolotti; Alberto Bazzocchi; Andrea Bolognesi; Letizia Polito
Journal:  Biomedicines       Date:  2018-02-10

7.  68Ga-Galmydar: A PET imaging tracer for noninvasive detection of Doxorubicin-induced cardiotoxicity.

Authors:  Jothilingam Sivapackiam; Shivesh Kabra; Sylvia Speidel; Monica Sharma; Richard Laforest; Amber Salter; Michael P Rettig; Vijay Sharma
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

8.  Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.

Authors:  Robert M Conry; Michael G Rodriguez; Joseph G Pressey
Journal:  Clin Sarcoma Res       Date:  2016-04-28

9.  BAG3 promotes chondrosarcoma progression by upregulating the expression of β-catenin.

Authors:  Huijuan Shi; Wenfang Chen; Yu Dong; Xiaofang Lu; Wenhui Zhang; Liantang Wang
Journal:  Mol Med Rep       Date:  2018-02-15       Impact factor: 2.952

10.  Response to PD1 inhibition in conventional chondrosarcoma.

Authors:  Michael J Wagner; Robert W Ricciotti; Jose Mantilla; Elizabeth T Loggers; Seth M Pollack; Lee D Cranmer
Journal:  J Immunother Cancer       Date:  2018-09-25       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.